Efficacy and safety of Anluohuaxian in the treatment of patients with severe Coronavirus disease 2019- a multicenter, open label, randomized controlled study: a structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: Patients with severe COVID-19 often suffer from significant pulmonary fibrosis. Although the pathogenesis of pulmonary fibrosis has not been fully explained, the signal pathways and cytokines involved are very similar to hepatic fibrosis. This has been successfully treated with the Anluo...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chi, Li, Jiawen, Wu, Zhao, Wang, He, Que, Chengli, Zhao, Hong, Wang, Guiqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/
https://www.ncbi.nlm.nih.gov/pubmed/32513299
http://dx.doi.org/10.1186/s13063-020-04399-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276971/
https://www.ncbi.nlm.nih.gov/pubmed/32513299
http://dx.doi.org/10.1186/s13063-020-04399-8

Ejemplares similares